[go: up one dir, main page]

SG11201608441YA - Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect - Google Patents

Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Info

Publication number
SG11201608441YA
SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA
Authority
SG
Singapore
Prior art keywords
prevention
salt
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
SG11201608441YA
Inventor
Takashi Mizutani
Chihoko Yoshimura
Hitomi Kondo
Makoto Kitade
Shuichi Ohkubo
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201608441YA publication Critical patent/SG11201608441YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201608441YA 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect SG11201608441YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (en) 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Publications (1)

Publication Number Publication Date
SG11201608441YA true SG11201608441YA (en) 2016-11-29

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608441YA SG11201608441YA (en) 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Country Status (21)

Country Link
US (2) US9963456B2 (en)
EP (1) EP3103802B1 (en)
JP (1) JP6192741B2 (en)
KR (1) KR101947289B1 (en)
CN (1) CN106661031B (en)
AU (1) AU2015281155B9 (en)
BR (1) BR112016025835B1 (en)
CA (1) CA2946833C (en)
DK (1) DK3103802T3 (en)
ES (1) ES2656772T3 (en)
HU (1) HUE037266T2 (en)
MX (1) MX2016015015A (en)
MY (1) MY183327A (en)
NO (1) NO3103802T3 (en)
PH (1) PH12016502130A1 (en)
PL (1) PL3103802T3 (en)
PT (1) PT3103802T (en)
RU (1) RU2658008C2 (en)
SG (1) SG11201608441YA (en)
TW (1) TWI605048B (en)
WO (1) WO2015199136A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (en) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
JP7125714B2 (en) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 2'-Deoxy-7-deazapurine nucleoside derivatives with antiviral activity
CA3087354C (en) * 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108640945B (en) * 2018-06-11 2020-10-23 广东工业大学 Amide compound and preparation method and application thereof
CN108822145B (en) * 2018-06-11 2020-10-23 广东工业大学 A kind of sulfonamide compound and its preparation method and application
WO2020014541A2 (en) * 2018-07-13 2020-01-16 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848718T3 (en) * 2005-02-04 2012-08-27 Millennium Pharm Inc E1 activation enzyme inhibitors
US7989430B2 (en) * 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
PT1989206E (en) 2006-02-02 2012-10-15 Millennium Pharm Inc Inhibitors of e1 activating enzyme
US20120115892A1 (en) 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
CN103298817A (en) 2011-01-07 2013-09-11 利奥制药有限公司 Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2738873A4 (en) * 2011-07-29 2015-04-01 Kuang Chi Innovative Tech Ltd ARTIFICIAL COMPOSITE MATERIAL AND ANTENNA CONSISTING OF ARTIFICIAL COMPOSITE MATERIAL
CN103958512B (en) * 2012-01-19 2016-01-20 大鹏药品工业株式会社 The two substituted alkynyl benzene compound of 3,5-and salt thereof

Also Published As

Publication number Publication date
PH12016502130B1 (en) 2016-12-19
KR20170016510A (en) 2017-02-13
AU2015281155B9 (en) 2017-11-16
RU2658008C2 (en) 2018-06-19
TWI605048B (en) 2017-11-11
MY183327A (en) 2021-02-18
US20180162864A1 (en) 2018-06-14
AU2015281155A1 (en) 2016-11-03
BR112016025835A2 (en) 2017-08-15
CA2946833A1 (en) 2015-12-30
CA2946833C (en) 2019-03-05
AU2015281155B2 (en) 2017-07-13
CN106661031B (en) 2019-07-23
ES2656772T3 (en) 2018-02-28
CN106661031A (en) 2017-05-10
MX2016015015A (en) 2017-02-27
JP6192741B2 (en) 2017-09-06
JPWO2015199136A1 (en) 2017-04-27
WO2015199136A1 (en) 2015-12-30
HUE037266T2 (en) 2018-08-28
PH12016502130A1 (en) 2016-12-19
PL3103802T3 (en) 2018-02-28
PT3103802T (en) 2017-12-11
EP3103802A4 (en) 2017-03-08
RU2016149319A (en) 2018-06-18
EP3103802A1 (en) 2016-12-14
RU2016149319A3 (en) 2018-06-18
BR112016025835B1 (en) 2022-09-20
US10174040B2 (en) 2019-01-08
NO3103802T3 (en) 2018-04-07
TW201625629A (en) 2016-07-16
EP3103802B1 (en) 2017-11-08
US20170066772A1 (en) 2017-03-09
DK3103802T3 (en) 2017-12-11
KR101947289B1 (en) 2019-02-12
US9963456B2 (en) 2018-05-08

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
SG11201608441YA (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
IL254720A0 (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
SI3672954T1 (en) Compounds, salts thereof and their use for the treatment of diseases
PL3065732T3 (en) Compounds, compositions and uses thereof for the prevention and/or treatment of dyslipidemia
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
HK1243935A1 (en) Organic compounds
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
IL263793A (en) Compounds and compositions for the treatment of cancer
EP3241551A4 (en) Pharmaceutical composition for treating cancer, containing lactate metal salt
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
IL275525A (en) Pharmaceutical composition for the treatment of cancer
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
HK1243936A1 (en) Organic compounds
EP3677267A4 (en) Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
EP3290051A4 (en) Pharmaceutical composition for treating and/or preventing cancer
PL3236961T3 (en) Pharmaceutical composition for preventing or treating cancer
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
IL252487B (en) Arylalkylamine compounds for use in the prevention or treatment of cancer
EP3267992A4 (en) Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases
EP3219323B8 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
HK1235391A1 (en) Inhibitors of creatine transport and uses thereof